期刊文献+

非小细胞肺癌表皮生长因子受体基因突变检测及其与临床病理特征的关系

Non-small Cell Lung Cancer Epidermal Growth Factor Receptor Gene Mu-tation Detection and Its Relationship with the Clinicopathological Character-istics
下载PDF
导出
摘要 目的探讨非小细胞肺癌(NSCLC)表皮生长因子受体(EGFR)基因突变情况及其与临床病理的关系。方法对2010年1月—2014年1月来该院诊治的159份非小细胞肺癌手术切除标本进行分析,实验中采用基因测序方法对标本中的EGFR基因突变情况进行检测,分析其与临床病理的关系。结果 159例样本中,EGFR基因突变检出率12.6%(20/159),突变主要集中在19号外显子的缺失和21号外显子的点突变。女性患者基因突变检出率明显高于男性患者(P﹤0.01)。腺癌及细支气管肺泡癌患者基因突变检出率明显高于其他组织学分型(P﹤0.01)。高分化患者基因突变检出率高于中-低分化检出率(P<0.05)。EGFR基因突变与年龄及淋巴结转移与否无关(P>0.05)。结论非小细胞肺癌患者EGFR基因突变与性别、组织学分型及分化程度密切相关。 Objective To investigate the non-small cell lung cancer(NSCLC) epidermal growth factor receptor(EGFR) gene mutation and its relationship with clinical pathology. Methods 159 patients with NSCLC were diagnosed and treated in our hospital from January 2010 to January 2014. And the surgical resection specimens of them were analyzed. Gene sequencing method was used to detect the EGFR gene mutation in the specimens, and the relationship between the EGFR gene mutation and clinical pathology was analyzed. Results In 159 samples, the EGFR gene mutation detection rate was 12.6%(20/159). The gene mutations mainly were the deletion in exon 19 and exon 21 point mutation. The gene mutation detection rate of the female patients was significantly higher than that of the male patients(P〈0.01). The gene mutation detection rates of adenocarcinoma and bronchioloalveolar carcinoma were significantly higher than those of other histological types(P〈0.01). The gene mutation detection rate of patients with high differentiation was higher than that of those with medium or low differentiation(P〈0.05). EGFR gene mutation had nothing to do with age, and the metastasis of lymph node(P〉0.05). Conclusion EGFR mutation in patients with non-small cell lung cancer is closely related with the sex, histological type and differentiation degree.
出处 《中外医疗》 2014年第28期9-11,共3页 China & Foreign Medical Treatment
关键词 肺肿瘤 非小细胞肺癌 表皮生长因子受体 基因突变 Lung neoplasms Non-small cell lung cancer Epidermal growth factor receptor Gene mutation
  • 相关文献

参考文献11

  • 1Scagliotti GV,Selvaggi G,Novello S,et al.The biology of epidermal growth factor receptor in lung cancer[J].Clin Cancer Res,2004,10(12Pt2):4227-4232.
  • 2Jemal A,Siegel R,Ward E,et al.Cancer statistic[J].CA Cancer J Clin,2006,56(2):106-130.
  • 3Mok TS,wu YL,Thongprasert S,et a1.Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,36l(10):947-957.
  • 4Zhou C,Wu YL,Chen G,et a1.Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive nonsmall-cell lung cancer(OPTIMAL,CTONG-0802):a multicentre,openlabel,randomised,phase 3 study[J].Lancet Oncol,2011,12(8):735-742.
  • 5Shi Y,Zhang L,Liu X,et al.Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer(ICOGEN):a randomised,double-blind phase 3 non-inferiority trial[J].Lancet Oncol,2013,14(10):953-961.
  • 6Kris MG,Matale RB,Herbst RS,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,insymptomatic patients with non-small cell lung cancer:a randomized trial[J].JAMA,2003,290(16):2149-2158.
  • 7Wu YL,Zhong WZ,Li LY,et a1.Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with nonsmall cell 1ung cancer:a meta—analysis based on updated individual patient data from six medical centers in China's Mainland[J].J Thorac Oncol,2007,2(5):430-439.
  • 8张晓彤,李龙芸,王树兰,穆新林,王孟昭.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志,2005,28(3):180-183. 被引量:31
  • 9Planchard D,Loriot Y,Besse B.[Impactof KRAS in stand-ard treatment of non-small cell lung cancer(NSCLC)pa-tients in 2009:prognostic and predictive value][J]1Bull Cancer,2009,96:S57-S68.
  • 10王芳,付莎,汤涛,邓玲,张晓,李银珍,邵建永.非小细胞肺癌表皮生长因子受体基因突变与临床病理特征的关系[J].中华病理学杂志,2011,40(10):664-666. 被引量:24

二级参考文献43

  • 1周彩存,周崧雯,潘虹,粟波,高志强.TaqMan—MGB探针实时荧光聚合酶链反应快速检测非小细胞肺癌表皮生长因子受体基因突变[J].中华肿瘤杂志,2007,29(2):119-123. 被引量:11
  • 2Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Nail Acad Sci U S A, 2004, 101(36) : 13306-13311.
  • 3Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Caner Res, 2004, 64 (24) : 8919-8923.
  • 4Sasaki H, Endo K, Takada M, et al. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer, 2007, 58 ( 3 ) : 324-328.
  • 5Whitcombe D, Theaker J, Guy SP, et al. Detection of PCR products using self-probing amplicans and fluorescence. Nat Biotechnol, 1999, 17(8) : 804-807.
  • 6Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res, 1989, 17 (7) :2503-2516.
  • 7Bates JA, Taylor EA. Scorpion ARMS primers for SNP real-time PCR detection and quantification of Pyrenophora teres. Mol Plant Pathol, 2001, 2(5):275-280.
  • 8Tomizawa Y, Iijima H, Sunaga N, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res, 2005, 11 (19 pt 1) :6816-6822.
  • 9Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer, 1996, 32A (12) : 2070-2074.
  • 10Tokumo M,Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small-cell lung cancers. Clin Cancer Res, 2005, 11(3) : 1167-1173.

共引文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部